


PHARMACEUTICAL 2023



Virpax Pharmaceuticals Inc. Rank 245 of 446





PHARMACEUTICAL 2023



Virpax Pharmaceuticals Inc. Rank 245 of 446

The relative strengths and weaknesses of Virpax Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Virpax Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 17% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	19,674
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,095
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	194
Other Revenues	0
Property and Equipment	0
Research and Development	10,763
Selling, General and Administrative Expense	11,082

Output Variable	Value in 1000 USD
Assets	19,674
Liabilities	3,095
Expenses	21,845
Revenues	0
Stockholders Equity	16,579
Net Income	-21,651
Comprehensive Net Income	-21,651
Economic Capital Ratio	60%

